<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00854620</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-04988</org_study_id>
    <secondary_id>96919</secondary_id>
    <secondary_id>SU-02272009-1898</secondary_id>
    <secondary_id>RENAL0009</secondary_id>
    <nct_id>NCT00854620</nct_id>
  </id_info>
  <brief_title>Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer</brief_title>
  <official_title>A Phase 2 Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma at Stanford University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine time-to-progression (TTP) for an escalating dose schedule for subjects with
      progressive metastatic renal cell carcinoma treated with sorafenib
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sorafenib to be administered as 28-day cycles.

      Sorafenib dose escalation by cycle is:

        -  Cycle 1: 400 mg BID

        -  Cycle 2: 600 mg BID

        -  Cycle 3+: 800 mg BID

      Within subject dose escalation and maximum dose is dependent on observed tolerability.

      Dose escalation only occurs after acceptable tolerability is demonstrated by subject.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-progression (TTP)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Kidney Disease</condition>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: 400 mg BID sorafenib
Cycle 2: 600 mg BID sorafenib
Cycle 3+: 800 mg BID sorafenib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)</description>
    <arm_group_label>Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
    <other_name>Sorafenib tosylate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically- or cytologically-confirmed metastatic or unresectable renal cell
             carcinoma (RCC).

          2. must have a component of conventional clear cell renal carcinoma.

          3. No more than one prior systemic therapy.

          4. No prior vascular endothelial growth factor receptor agents.

          5. Prior palliative radiotherapy in metastatic lesion(s) is permitted, provided the
             subject has at least one measurable and/or evaluable lesion(s) that has not been
             irradiated.

          6. All major surgery of any type and/or radiotherapy must be completed at least 4 weeks
             prior to Day 1 dosing. Patients must have recovered from surgery and/or radiotherapy
             toxicity prior to Day 1 dosing.

          7. Measureable disease by RECIST criteria

          8. Karnofsky performance status at least 70% or ECOG not more than 2

          9. Ability to give written informed consent

         10. At least 18 years old

         11. Negative pregnancy test within 7 days of Day 1 dosing (female subjects of childbearing
             potential)

         12. Sexually active fertile subjects must agree to use an accepted method of contraception
             during the course of the study for 3 months thereafter.

         13. ANC at least 1,500/uL

         14. Platelet count at least 100,000/uL

         15. AST/ALT not more than 2.5 times the upper limit of normal (ULN)

         16. Alkaline phosphatase not more than 2.5 x ULN

         17. Serum bilirubin not more than 1.5 x ULN

         18. Amylase/Lipase within normal range

         19. Urinalysis not more than 1+ protein

         20. Serum creatinine not more than 1.5 x ULN

         21. No active ischemia by ECG

         22. Echocardiogram or MUGA ejection fraction at least 40%

        Exclusion Criteria:

          1. Ongoing hemoptysis

          2. Cerebrovascular accident within 12 months

          3. Peripheral vascular disease with claudication on less than 1 block

          4. History of clinically significant bleeding

          5. Malignancy with true papillary/sarcomatoid features without any clear cell component

          6. Chromophobe

          7. Oncocytoma

          8. Collecting duct tumors

          9. Transitional cell carcinoma

         10. Deep venous thrombosis or pulmonary embolus within one year of consent

         11. Ongoing need for full-dose oral or parenteral anticoagulation. Low dose coumadin (1
             mg) for maintenance of catheter patency or daily prophylactic aspirin is allowed

         12. Subjects with evidence of current central nervous system (CNS) metastases

         13. MRI or CT scan of the brain (with contrast, if possible) within 28 days prior to Day 1
             dosing

         14. Significant cardiovascular disease defined as congestive heart failure (New York Heart
             Association Class II, II or IV)

         15. Angina pectoris requiring nitrate therapy

         16. Myocardial infarction within the last 6 months

         17. Uncontrolled hypertension (defined as blood pressure at least 160 mmHg systolic or at
             least 90 mmHg diastolic on medication)

         18. Ongoing requirement for systemic corticosteroid therapy (except replacement therapy
             for adrenal insufficiency). Topical and/or inhaled steroids are allowed.

         19. Uncontrolled psychiatric disorder

         20. Delayed healing of wounds, ulcers, and/or bone fractures

         21. Prior malignancy (EXCEPTIONS: adequately-treated basal cell or squamous cell skin
             cancer or any other cancer for which chemotherapy has been completed &gt; 5 years ago and
             from which the patient has been disease-free for &gt; 5 years)

         22. Pregnant

         23. Currently lactating

         24. Currently using St John's Wort (an herb)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Sandy Srinivas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2009</study_first_posted>
  <results_first_submitted>January 6, 2015</results_first_submitted>
  <results_first_submitted_qc>January 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2015</results_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sandy Srinivas</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib</title>
          <description>Cycle 1: 400 mg BID sorafenib
Cycle 2: 600 mg BID sorafenib
Cycle 3+: 800 mg BID sorafenib
Sorafenib: Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects enrolled were included in the analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib</title>
          <description>Cycle 1: 400 mg BID sorafenib
Cycle 2: 600 mg BID sorafenib
Cycle 3+: 800 mg BID sorafenib
Sorafenib: Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="47" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-to-progression (TTP)</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib</title>
            <description>Cycle 1: 400 mg BID sorafenib
Cycle 2: 600 mg BID sorafenib
Cycle 3+: 800 mg BID sorafenib
Sorafenib: Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-progression (TTP)</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="0.9" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib</title>
          <description>Cycle 1: 400 mg BID sorafenib
Cycle 2: 600 mg BID sorafenib
Cycle 3+: 800 mg BID sorafenib
Sorafenib: Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAEv4</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions-other, Hand foot Syndrome</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sandy Srinivas, MD</name_or_title>
      <organization>Stanford University, Stanford Cancer Center</organization>
      <phone>650-725-2078</phone>
      <email>sandysri@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

